Serum kisspeptin as a promising biomarker for PCOS: a mini review of current evidence and future prospects.

Clinical Diabetes and Endocrinology Pub Date : 2024-09-30 DOI:10.1186/s40842-024-00190-9

Emmanuel Kokori, Gbolahan Olatunji, Rosemary Komolafe, Ikponmwosa Jude Ogieuhi, Bonaventure Ukoaka, Irene Ajayi, Nicholas Aderinto

{"title":"Serum kisspeptin as a promising biomarker for PCOS: a mini review of current evidence and future prospects.","authors":"Emmanuel Kokori, Gbolahan Olatunji, Rosemary Komolafe, Ikponmwosa Jude Ogieuhi, Bonaventure Ukoaka, Irene Ajayi, Nicholas Aderinto","doi":"10.1186/s40842-024-00190-9","DOIUrl":null,"url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, characterised by its multifactorial nature and intricate interplay of genetic, hormonal, and environmental factors. As the search for reliable biomarkers intensifies, serum kisspeptin emerges as a promising candidate due to its central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. This review aims to consolidate the evolving understanding of kisspeptin as a potential PCOS biomarker, comprehensively exploring its physiological basis, diagnostic challenges in PCOS, and clinical implications. Diagnostic challenges in PCOS are addressed, underscoring the limitations of current criteria and the need for objective and standardised biomarkers. Kisspeptin's introduction as a potential biomarker brings forth both promises and challenges in terms of its diagnostic utility. The review recognises the importance of standardisation in research methodologies and emphasises the exploration of genetic polymorphisms to enhance kisspeptin's robustness as a diagnostic tool.</p>","PeriodicalId":56339,"journal":{"name":"Clinical Diabetes and Endocrinology","volume":"10 1","pages":"27"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440685/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes and Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40842-024-00190-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, characterised by its multifactorial nature and intricate interplay of genetic, hormonal, and environmental factors. As the search for reliable biomarkers intensifies, serum kisspeptin emerges as a promising candidate due to its central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. This review aims to consolidate the evolving understanding of kisspeptin as a potential PCOS biomarker, comprehensively exploring its physiological basis, diagnostic challenges in PCOS, and clinical implications. Diagnostic challenges in PCOS are addressed, underscoring the limitations of current criteria and the need for objective and standardised biomarkers. Kisspeptin's introduction as a potential biomarker brings forth both promises and challenges in terms of its diagnostic utility. The review recognises the importance of standardisation in research methodologies and emphasises the exploration of genetic polymorphisms to enhance kisspeptin's robustness as a diagnostic tool.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血清吻肽作为多囊卵巢综合征的一种有前途的生物标志物：对当前证据和未来前景的小型回顾。

多囊卵巢综合征（PCOS）是一种影响育龄妇女的常见内分泌疾病，其特点是多因素性以及遗传、激素和环境因素的复杂相互作用。随着人们对可靠生物标志物的探索不断深入，血清吻肽（kisspeptin）因其在调节下丘脑-垂体-性腺轴（HPG）中的核心作用而成为一个很有希望的候选指标。本综述旨在巩固人们对作为潜在多囊卵巢综合症生物标志物的吻肽（kisspeptin）不断发展的认识，全面探讨其生理基础、多囊卵巢综合症的诊断难题和临床意义。文章探讨了多囊卵巢综合症的诊断难题，强调了当前标准的局限性以及对客观、标准化生物标志物的需求。Kisspeptin 作为一种潜在的生物标志物的引入，为其诊断效用带来了希望和挑战。综述认识到研究方法标准化的重要性，并强调了对基因多态性的探索，以增强 Kisspeptin 作为诊断工具的稳健性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Diabetes and Endocrinology

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Diabetes and Endocrinology is an open access journal publishing within the field of diabetes and endocrine disease. The journal aims to provide a widely available resource for people working within the field of diabetes and endocrinology, in order to improve the care of people affected by these conditions. The audience includes, but is not limited to, physicians, researchers, nurses, nutritionists, pharmacists, podiatrists, psychologists, epidemiologists, exercise physiologists and health care researchers. Research articles include patient-based research (clinical trials, clinical studies, and others), translational research (translation of basic science to clinical practice, translation of clinical practice to policy and others), as well as epidemiology and health care research. Clinical articles include case reports, case seminars, consensus statements, clinical practice guidelines and evidence-based medicine. Only articles considered to contribute new knowledge to the field will be considered for publication.